New Zealand markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
57.98-0.16 (-0.28%)
At close: 04:00PM EST
57.04 -0.94 (-1.62%)
After hours: 05:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close58.14
Bid0.00 x 900
Ask0.00 x 800
Day's range57.67 - 58.26
52-week range31.45 - 74.49
Avg. volume2,605,652
Market cap10.479B
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

    Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

  • Zacks

    Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

    Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

  • Reuters

    UPDATE 3-Catalent sales edge past estimates as focus shifts to Novo deal

    Contract drug manufacturer Catalent inched past Wall Street estimates for second-quarter revenue on Friday, days after it agreed to a $16.5-billion buyout offer from Novo Nordisk's parent firm. The New Jersey-based firm is the main supplier of fill-finish work - involving filling and packaging syringes and injection pens in sterile conditions - for Novo's popular weight-loss drug, Wegovy. Catalent's shares were marginally higher at $56.70, compared with Novo's offer of $63.50 per share.